Hormonal
Intravenous administration of exendin-4 (0.05 pmol/kg/min) significantly reduces fasting and postprandial plasma glucose levels and decreases caloric intake by 19% in healthy volunteers without causing nausea.
Exendin-4, a GLP-1 receptor agonist, significantly lowers blood glucose and reduces calorie intake in healthy individuals without causing nausea at the tested dose. It works by delaying gastric emptying and reducing hunger, offering a potential treatment for type 2 diabetes and obesity.
Exendin-4 reduced fasting plasma glucose levels and reduced the peak change of postprandial glucose from baseline... Volunteers consumed 19% fewer calories at a free-choice buffet lunch with exendin-4... without reported side effects.
Why this rating
Randomized, double-blind, placebo-controlled trial in healthy humans, though sample size is small (n=8).
Source
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
C. M. B. Edwards et al. · American Journal of Physiology-Endocrinology and Metabolism · 2001
DOI 10.1152/ajpendo.2001.281.1.e155
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →